 Shares of Molecular Partners Inc. MOLN, -36.67 slid 37.3 in premarket trading on Wednesday, the day after the company said Amgen Inc. AMGN, -0.91 returned the global rights to an investigational oncology therapy currently in a Phase 1 clinical trial targeting solid tumors. Amgens stock was up 0.3 in the premarket on Wednesday. 